Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Piracetam in elderly motorists.

U Schmidt¹, D Brendemühl, K Engels

¹Arbeits- und Forschungsgemeinschaft für Strassenverkehr und Verkehrssicherheit, University of Cologne, Germany.

Pharmacopsychiatry

|July 1, 1991

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

ESMO open·2025

Same author

Congruent direction but different magnitude of biodiversity response to land-use intensification in space and time.

Nature ecology & evolution·2025

Same author

Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.

Breast cancer research and treatment·2017

Piracetam significantly improved driving performance in elderly motorists with reduced reaction times. This cognitive enhancer enhanced orientation and perception, benefiting drivers who initially scored below 80% on tests.

Area of Science:

Gerontology
Neuroscience
Traffic Safety

Background:

Elderly drivers often experience reduced reaction capacity, impacting driving ability.
Cognitive function, including orientation and perception, is crucial for safe driving.

Purpose of the Study:

To evaluate the effect of piracetam on the driving performance of elderly motorists with diminished reaction capacity.
To assess piracetam's impact on orientation and perception under real traffic conditions.

Main Methods:

A randomized, double-blind, placebo-controlled study involving 101 elderly drivers.
Participants received a daily dose of 4.8g piracetam or placebo for six weeks.
Driving ability was assessed using sign-observance items reflecting real traffic conditions.

Related Experiment Videos

Main Results:

Piracetam-treated drivers improved sign-observance scores from 77.08% to 84.16%, significantly outperforming the placebo group (79.86% to 80.07%).
All participants scoring below 80% pre-treatment showed improvement after piracetam administration.
Piracetam treatment led to a significant enhancement in driving performance compared to placebo.

Conclusions:

Piracetam demonstrates efficacy in improving cognitive functions related to driving in elderly individuals with reduced reaction capacity.
The findings suggest piracetam as a potential intervention to enhance road safety for vulnerable elderly drivers.